These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31014551)

  • 1. Clinical experience with different initial doses of tolvaptan in SIADH.
    Barajas-Galindo DE; Vidal-Casariego A; Gómez-Hoyos E; Fernández-Martínez P; Guerra González M; Hernández-Moreno A; Alejo-Ramos M; Villar-Taibo R; Cano-Rodríguez I; Ballesteros-Pomar MD
    Nefrologia (Engl Ed); 2019; 39(6):672-674. PubMed ID: 31014551
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
    Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lower doses of tolvaptan in hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion].
    Sánchez Sobrino P; Fernández Catalina P; Lorenzo Solar M; Rego Iraeta A
    Med Clin (Barc); 2015 Aug; 145(3):138-9. PubMed ID: 25543222
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants.
    Marx-Berger D; Milford DV; Bandhakavi M; Van't Hoff W; Kleta R; Dattani M; Bockenhauer D
    Acta Paediatr; 2016 Jul; 105(7):e334-7. PubMed ID: 27028950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH).
    Harbeck B; Lindner U; Haas CS
    Endocrine; 2016 Sep; 53(3):872-3. PubMed ID: 26961548
    [No Abstract]   [Full Text] [Related]  

  • 6. A new method of intermittent lower dose of tolvaptan combined with fluid restriction to treat the syndrome of inappropriate antidiuresis: A case report.
    Yuan X; Pan H; Zhu H; Li J; Miao H; Ke X; Chen S
    Medicine (Baltimore); 2019 Oct; 98(43):e17586. PubMed ID: 31651865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) due to bortezomib in a case of light chain multiple mieloma. Treatment with tolvaptan.
    Carreño A; Hernández B; Mayoralas Á; Calle C
    Nefrologia; 2017; 37(5):558-559. PubMed ID: 28946972
    [No Abstract]   [Full Text] [Related]  

  • 8. Relapsing Syndrome of Inappropriate Antidiuretic Hormone Production Responding to Tolvaptan Treatment in a Patient With a Micronodular Formation of the Posterior Pituitary Gland.
    Reinke LM; Seoudy AK; Gärtner F; Rohmann N; Schulte DM; Schreiber S; Jansen O; Laudes M
    Exp Clin Endocrinol Diabetes; 2023 Sep; 131(9):472-475. PubMed ID: 37364592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan for SIADH in Myelodysplastic Syndrome with Blast Crisis.
    Mali P; Muduganti SR; Mujibur R; Murali N
    WMJ; 2015 Apr; 114(2):66-8. PubMed ID: 26756059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
    Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
    BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience.
    Park GH; Lee CM; Song JW; Jung MC; Kim JK; Song YR; Kim HJ; Kim SG
    Korean J Intern Med; 2018 May; 33(3):561-567. PubMed ID: 28286940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
    Bordi P; Tiseo M; Buti S; Regolisti G; Ardizzoni A
    Tumori; 2015 Apr; 101(2):e51-3. PubMed ID: 25702667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: when tolvaptan becomes a life saving drug.
    Graziani G; Cucchiari D; Aroldi A; Angelini C; Gaetani P; Selmi C
    J Neurol Neurosurg Psychiatry; 2012 May; 83(5):510-2. PubMed ID: 22323742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
    Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
    De Las Peñas R; Ponce S; Henao F; Camps Herrero C; Carcereny E; Escobar Álvarez Y; Rodríguez CA; Virizuela JA; López López R
    Support Care Cancer; 2016 Jan; 24(1):499-507. PubMed ID: 26431960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
    Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults.
    Shoaf SE; Bricmont P; Dandurand A
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1399-1408. PubMed ID: 28803333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
    Humayun MA; Cranston IC
    BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
    Pose-Reino A; Runkle de la Vega I; de Jong-Laird A; Kabra M; Lindner U
    Adv Ther; 2021 Feb; 38(2):1055-1067. PubMed ID: 33306187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.